| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lyme Disease | 18 | 2023 | 122 | 5.960 |
Why?
|
| Erythema Chronicum Migrans | 7 | 2023 | 9 | 2.990 |
Why?
|
| Emergency Service, Hospital | 13 | 2024 | 1093 | 1.840 |
Why?
|
| Anti-Bacterial Agents | 11 | 2021 | 784 | 1.530 |
Why?
|
| Glossitis, Benign Migratory | 2 | 2023 | 2 | 1.530 |
Why?
|
| Relapsing Fever | 2 | 2021 | 17 | 1.390 |
Why?
|
| Syphilis | 2 | 2021 | 25 | 1.370 |
Why?
|
| Postural Orthostatic Tachycardia Syndrome | 9 | 2023 | 37 | 1.340 |
Why?
|
| Humans | 177 | 2025 | 63283 | 1.330 |
Why?
|
| Infant, Premature | 13 | 2025 | 184 | 1.280 |
Why?
|
| Female | 128 | 2025 | 32776 | 1.260 |
Why?
|
| Male | 105 | 2025 | 29799 | 1.200 |
Why?
|
| Patient Admission | 5 | 2020 | 195 | 1.150 |
Why?
|
| Doxycycline | 4 | 2021 | 46 | 1.050 |
Why?
|
| Cerebral Hemorrhage | 6 | 2014 | 96 | 1.010 |
Why?
|
| Middle Aged | 60 | 2025 | 17535 | 0.950 |
Why?
|
| Adult | 62 | 2025 | 16771 | 0.940 |
Why?
|
| Infant, Newborn | 37 | 2025 | 1355 | 0.880 |
Why?
|
| Emergency Nursing | 3 | 2017 | 19 | 0.880 |
Why?
|
| Indomethacin | 2 | 2014 | 22 | 0.850 |
Why?
|
| Neonatal Abstinence Syndrome | 4 | 2021 | 37 | 0.840 |
Why?
|
| Length of Stay | 9 | 2019 | 811 | 0.820 |
Why?
|
| Retrospective Studies | 48 | 2023 | 6627 | 0.800 |
Why?
|
| Confidence Intervals | 4 | 2020 | 240 | 0.790 |
Why?
|
| Hypoventilation | 1 | 2022 | 4 | 0.780 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2020 | 57 | 0.780 |
Why?
|
| Laboratories, Hospital | 1 | 2022 | 10 | 0.780 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2022 | 19 | 0.770 |
Why?
|
| Coronary Stenosis | 1 | 2022 | 39 | 0.760 |
Why?
|
| Infant, Premature, Diseases | 7 | 2022 | 47 | 0.750 |
Why?
|
| Analgesics, Opioid | 4 | 2021 | 536 | 0.740 |
Why?
|
| Academic Medical Centers | 5 | 2018 | 318 | 0.730 |
Why?
|
| Phenobarbital | 3 | 2020 | 13 | 0.720 |
Why?
|
| Syncope, Vasovagal | 5 | 2020 | 8 | 0.720 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2020 | 7 | 0.700 |
Why?
|
| Prospective Studies | 18 | 2024 | 3280 | 0.690 |
Why?
|
| Cardiovascular Agents | 2 | 2019 | 104 | 0.690 |
Why?
|
| Aged | 42 | 2025 | 14384 | 0.680 |
Why?
|
| Quality of Life | 4 | 2015 | 1223 | 0.660 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2020 | 28 | 0.660 |
Why?
|
| Cardiac Rehabilitation | 4 | 2022 | 67 | 0.640 |
Why?
|
| Biomedical Research | 2 | 2020 | 268 | 0.630 |
Why?
|
| Thiamine | 1 | 2019 | 21 | 0.620 |
Why?
|
| Epidural Abscess | 1 | 2018 | 9 | 0.570 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 2 | 2014 | 7 | 0.550 |
Why?
|
| Young Adult | 22 | 2021 | 4683 | 0.550 |
Why?
|
| Clonidine | 2 | 2014 | 25 | 0.550 |
Why?
|
| Cardiac Output | 6 | 2020 | 28 | 0.550 |
Why?
|
| Morphine | 2 | 2014 | 59 | 0.540 |
Why?
|
| Patient Transfer | 4 | 2018 | 93 | 0.530 |
Why?
|
| Models, Statistical | 2 | 2018 | 309 | 0.530 |
Why?
|
| Infant, Very Low Birth Weight | 2 | 2014 | 38 | 0.520 |
Why?
|
| Delivery of Health Care | 2 | 2018 | 436 | 0.520 |
Why?
|
| Quality Improvement | 3 | 2017 | 442 | 0.510 |
Why?
|
| Hospitalization | 9 | 2021 | 1355 | 0.510 |
Why?
|
| Opioid-Related Disorders | 3 | 2021 | 498 | 0.490 |
Why?
|
| Aged, 80 and over | 18 | 2022 | 5443 | 0.480 |
Why?
|
| Fatigue | 1 | 2016 | 111 | 0.480 |
Why?
|
| Aging | 3 | 2018 | 746 | 0.480 |
Why?
|
| Fever | 3 | 2018 | 66 | 0.470 |
Why?
|
| Erythema | 3 | 2020 | 13 | 0.470 |
Why?
|
| Adolescent | 29 | 2023 | 6238 | 0.470 |
Why?
|
| Quality of Health Care | 7 | 2020 | 519 | 0.470 |
Why?
|
| Reminder Systems | 1 | 2016 | 74 | 0.470 |
Why?
|
| Risk Assessment | 5 | 2021 | 2071 | 0.470 |
Why?
|
| Spectroscopy, Near-Infrared | 2 | 2022 | 41 | 0.460 |
Why?
|
| Patient Satisfaction | 4 | 2020 | 433 | 0.460 |
Why?
|
| Patient Discharge | 6 | 2022 | 511 | 0.440 |
Why?
|
| ST Elevation Myocardial Infarction | 3 | 2024 | 90 | 0.440 |
Why?
|
| Patient Handoff | 1 | 2014 | 35 | 0.430 |
Why?
|
| Heart Rate | 8 | 2023 | 321 | 0.430 |
Why?
|
| Infant | 18 | 2023 | 1649 | 0.430 |
Why?
|
| Electronic Health Records | 2 | 2023 | 358 | 0.430 |
Why?
|
| Heart Failure | 2 | 2019 | 913 | 0.430 |
Why?
|
| Treatment Outcome | 26 | 2020 | 5647 | 0.420 |
Why?
|
| Spermatic Cord Torsion | 1 | 2013 | 13 | 0.420 |
Why?
|
| Vascular Resistance | 6 | 2019 | 48 | 0.420 |
Why?
|
| Percutaneous Coronary Intervention | 4 | 2018 | 208 | 0.420 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2016 | 715 | 0.410 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 205 | 0.400 |
Why?
|
| Oxygen Consumption | 1 | 2013 | 209 | 0.400 |
Why?
|
| Nursing Staff, Hospital | 1 | 2013 | 67 | 0.400 |
Why?
|
| Testis | 1 | 2013 | 149 | 0.390 |
Why?
|
| Transfusion Reaction | 4 | 2018 | 46 | 0.390 |
Why?
|
| Ambulances | 1 | 2012 | 24 | 0.390 |
Why?
|
| Intensive Care Units, Neonatal | 6 | 2020 | 81 | 0.390 |
Why?
|
| Catheterization, Central Venous | 2 | 2012 | 87 | 0.390 |
Why?
|
| Nurse's Role | 1 | 2013 | 120 | 0.380 |
Why?
|
| Bacteremia | 2 | 2012 | 94 | 0.380 |
Why?
|
| Physicians | 3 | 2014 | 471 | 0.380 |
Why?
|
| Hand Disinfection | 1 | 2012 | 18 | 0.380 |
Why?
|
| Babesiosis | 3 | 2019 | 12 | 0.370 |
Why?
|
| Oxygen | 1 | 2013 | 315 | 0.370 |
Why?
|
| Fetal Membranes, Premature Rupture | 5 | 2019 | 12 | 0.370 |
Why?
|
| Congenital Abnormalities | 2 | 2013 | 26 | 0.370 |
Why?
|
| Depression | 1 | 2018 | 891 | 0.370 |
Why?
|
| Borrelia burgdorferi | 6 | 2017 | 90 | 0.370 |
Why?
|
| Infant, Low Birth Weight | 4 | 2022 | 60 | 0.360 |
Why?
|
| Vasodilator Agents | 1 | 2011 | 68 | 0.360 |
Why?
|
| Adenosine | 1 | 2011 | 78 | 0.360 |
Why?
|
| Pregnancy | 21 | 2023 | 2330 | 0.350 |
Why?
|
| Hallucinations | 1 | 2010 | 16 | 0.350 |
Why?
|
| Medical Staff | 1 | 2010 | 13 | 0.350 |
Why?
|
| Vibration | 1 | 2010 | 26 | 0.350 |
Why?
|
| Cohort Studies | 17 | 2020 | 2566 | 0.350 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 730 | 0.350 |
Why?
|
| Child | 20 | 2022 | 4522 | 0.350 |
Why?
|
| Femoral Artery | 1 | 2011 | 110 | 0.340 |
Why?
|
| Vasoconstriction | 4 | 2019 | 22 | 0.340 |
Why?
|
| New York | 11 | 2019 | 144 | 0.330 |
Why?
|
| United States | 16 | 2024 | 7828 | 0.330 |
Why?
|
| Hypotension, Orthostatic | 2 | 2020 | 27 | 0.330 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 4 | 2025 | 12 | 0.320 |
Why?
|
| Risk Factors | 21 | 2021 | 5338 | 0.320 |
Why?
|
| Guideline Adherence | 1 | 2012 | 306 | 0.320 |
Why?
|
| Erythrocyte Transfusion | 3 | 2017 | 74 | 0.320 |
Why?
|
| Motivation | 1 | 2012 | 285 | 0.310 |
Why?
|
| Premature Birth | 2 | 2011 | 112 | 0.310 |
Why?
|
| Child, Preschool | 16 | 2020 | 1988 | 0.310 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 172 | 0.310 |
Why?
|
| Inservice Training | 1 | 2009 | 86 | 0.310 |
Why?
|
| Postoperative Complications | 4 | 2017 | 1304 | 0.310 |
Why?
|
| Sensitivity and Specificity | 7 | 2018 | 1146 | 0.310 |
Why?
|
| Eczema | 1 | 2009 | 9 | 0.310 |
Why?
|
| Medication Errors | 1 | 2009 | 109 | 0.310 |
Why?
|
| Patient Dropouts | 2 | 2020 | 49 | 0.300 |
Why?
|
| Cross Infection | 4 | 2015 | 162 | 0.300 |
Why?
|
| Leukomalacia, Periventricular | 6 | 2001 | 10 | 0.300 |
Why?
|
| Referral and Consultation | 6 | 2022 | 422 | 0.300 |
Why?
|
| Neoplasms | 3 | 2017 | 1359 | 0.300 |
Why?
|
| Hyperventilation | 2 | 2018 | 7 | 0.300 |
Why?
|
| Patient Readmission | 4 | 2022 | 430 | 0.300 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 590 | 0.300 |
Why?
|
| Lower Body Negative Pressure | 3 | 2017 | 8 | 0.290 |
Why?
|
| Labor, Induced | 2 | 2020 | 25 | 0.290 |
Why?
|
| Time-to-Treatment | 2 | 2020 | 111 | 0.290 |
Why?
|
| Vomiting | 1 | 2009 | 137 | 0.290 |
Why?
|
| Case-Control Studies | 9 | 2020 | 1121 | 0.290 |
Why?
|
| Gastroesophageal Reflux | 1 | 2009 | 92 | 0.290 |
Why?
|
| Massachusetts | 10 | 2019 | 2075 | 0.290 |
Why?
|
| Patient Care Team | 3 | 2023 | 337 | 0.290 |
Why?
|
| Child Development | 2 | 2009 | 85 | 0.280 |
Why?
|
| Program Evaluation | 4 | 2017 | 488 | 0.280 |
Why?
|
| Tidal Volume | 2 | 2025 | 41 | 0.280 |
Why?
|
| Catheter-Related Infections | 2 | 2021 | 42 | 0.270 |
Why?
|
| Computer Literacy | 1 | 2007 | 3 | 0.270 |
Why?
|
| Government Agencies | 1 | 2007 | 10 | 0.270 |
Why?
|
| Positive-Pressure Respiration | 2 | 2025 | 51 | 0.270 |
Why?
|
| Public Health Administration | 1 | 2007 | 23 | 0.270 |
Why?
|
| Information Systems | 1 | 2007 | 29 | 0.270 |
Why?
|
| Risk | 2 | 2014 | 377 | 0.270 |
Why?
|
| omega-N-Methylarginine | 2 | 2017 | 8 | 0.270 |
Why?
|
| Reproducibility of Results | 8 | 2024 | 1649 | 0.270 |
Why?
|
| Autistic Disorder | 3 | 2022 | 151 | 0.270 |
Why?
|
| Nitric Oxide Synthase | 2 | 2017 | 47 | 0.260 |
Why?
|
| Efficiency, Organizational | 2 | 2017 | 96 | 0.260 |
Why?
|
| Patient Safety | 2 | 2020 | 243 | 0.260 |
Why?
|
| Blood Volume | 3 | 2018 | 42 | 0.260 |
Why?
|
| Hyperemia | 2 | 2017 | 13 | 0.260 |
Why?
|
| Seizures | 2 | 2020 | 143 | 0.260 |
Why?
|
| Liver Cirrhosis | 3 | 2014 | 171 | 0.250 |
Why?
|
| Gestational Age | 6 | 2015 | 189 | 0.250 |
Why?
|
| Hospitalists | 2 | 2019 | 37 | 0.250 |
Why?
|
| Teaching | 2 | 2016 | 159 | 0.250 |
Why?
|
| Cerebrovascular Disorders | 1 | 2006 | 81 | 0.250 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 1199 | 0.240 |
Why?
|
| Obstetric Labor, Premature | 5 | 1999 | 31 | 0.240 |
Why?
|
| Psychomotor Performance | 2 | 2017 | 137 | 0.240 |
Why?
|
| Delivery Rooms | 2 | 2025 | 4 | 0.240 |
Why?
|
| Asthma | 3 | 2009 | 440 | 0.240 |
Why?
|
| New York City | 4 | 2022 | 80 | 0.240 |
Why?
|
| Pregnancy Complications | 5 | 2019 | 377 | 0.230 |
Why?
|
| Anaplasmosis | 1 | 2025 | 5 | 0.230 |
Why?
|
| Ehrlichiosis | 1 | 2025 | 6 | 0.230 |
Why?
|
| Patients | 2 | 2020 | 113 | 0.230 |
Why?
|
| Anaplasma phagocytophilum | 1 | 2025 | 9 | 0.230 |
Why?
|
| Registries | 3 | 2013 | 884 | 0.230 |
Why?
|
| Problem Solving | 1 | 2004 | 32 | 0.230 |
Why?
|
| Enzyme Inhibitors | 2 | 2017 | 373 | 0.230 |
Why?
|
| Language Tests | 1 | 2004 | 39 | 0.230 |
Why?
|
| Polysomnography | 2 | 2022 | 57 | 0.220 |
Why?
|
| Vaccination | 2 | 2022 | 363 | 0.220 |
Why?
|
| Incidence | 11 | 2022 | 1375 | 0.220 |
Why?
|
| Anticonvulsants | 3 | 2020 | 107 | 0.220 |
Why?
|
| Blood Pressure | 7 | 2023 | 509 | 0.220 |
Why?
|
| Time Factors | 9 | 2020 | 3757 | 0.220 |
Why?
|
| Predictive Value of Tests | 5 | 2021 | 1084 | 0.220 |
Why?
|
| Europe | 3 | 2021 | 194 | 0.220 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2004 | 16 | 0.220 |
Why?
|
| Posture | 3 | 2019 | 127 | 0.220 |
Why?
|
| Nails, Malformed | 1 | 2004 | 6 | 0.220 |
Why?
|
| Debridement | 1 | 2004 | 34 | 0.210 |
Why?
|
| Pilot Projects | 5 | 2022 | 1006 | 0.210 |
Why?
|
| Surveys and Questionnaires | 6 | 2016 | 2675 | 0.210 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2004 | 34 | 0.210 |
Why?
|
| Hospitals | 3 | 2023 | 393 | 0.210 |
Why?
|
| Patient Education as Topic | 4 | 2013 | 474 | 0.210 |
Why?
|
| Coronary Artery Bypass | 2 | 2017 | 297 | 0.210 |
Why?
|
| Cerebrovascular Circulation | 4 | 2018 | 180 | 0.210 |
Why?
|
| Diastole | 2 | 2022 | 91 | 0.210 |
Why?
|
| Disinfection | 2 | 2015 | 22 | 0.210 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2020 | 30 | 0.210 |
Why?
|
| Marijuana Use | 1 | 2023 | 21 | 0.210 |
Why?
|
| Time | 1 | 2023 | 30 | 0.210 |
Why?
|
| Acute Disease | 3 | 2021 | 672 | 0.200 |
Why?
|
| Prevalence | 7 | 2013 | 1377 | 0.200 |
Why?
|
| Triage | 2 | 2024 | 127 | 0.200 |
Why?
|
| Coronary Angiography | 2 | 2016 | 201 | 0.200 |
Why?
|
| Lead Poisoning | 1 | 2022 | 10 | 0.200 |
Why?
|
| Dwarfism | 1 | 2022 | 15 | 0.200 |
Why?
|
| Demyelinating Diseases | 2 | 2000 | 16 | 0.200 |
Why?
|
| Point-of-Care Testing | 1 | 2023 | 43 | 0.200 |
Why?
|
| Human Growth Hormone | 1 | 2022 | 19 | 0.200 |
Why?
|
| Restaurants | 1 | 2022 | 12 | 0.200 |
Why?
|
| Cannabis | 1 | 2023 | 51 | 0.200 |
Why?
|
| Age Factors | 6 | 2017 | 1560 | 0.200 |
Why?
|
| Tilt-Table Test | 5 | 2020 | 11 | 0.200 |
Why?
|
| Chorioamnionitis | 5 | 2020 | 14 | 0.190 |
Why?
|
| Hospitals, Community | 1 | 2022 | 71 | 0.190 |
Why?
|
| Constriction, Pathologic | 1 | 2022 | 129 | 0.190 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2022 | 32 | 0.190 |
Why?
|
| Central Nervous System Stimulants | 1 | 2022 | 65 | 0.190 |
Why?
|
| Education, Medical, Graduate | 2 | 2015 | 350 | 0.190 |
Why?
|
| Skin | 2 | 2023 | 373 | 0.190 |
Why?
|
| Exercise Test | 2 | 2021 | 252 | 0.190 |
Why?
|
| Risk Management | 2 | 2018 | 39 | 0.190 |
Why?
|
| Aftercare | 1 | 2022 | 76 | 0.190 |
Why?
|
| Retinopathy of Prematurity | 1 | 2022 | 13 | 0.190 |
Why?
|
| Follow-Up Studies | 8 | 2017 | 2460 | 0.190 |
Why?
|
| Epiglottitis | 1 | 2021 | 6 | 0.190 |
Why?
|
| Crowding | 3 | 2019 | 34 | 0.190 |
Why?
|
| Trauma Centers | 1 | 2022 | 123 | 0.180 |
Why?
|
| Bone Marrow Examination | 1 | 2001 | 8 | 0.180 |
Why?
|
| Anesthesia, Intravenous | 1 | 2001 | 14 | 0.180 |
Why?
|
| Parents | 2 | 2020 | 390 | 0.180 |
Why?
|
| Spinal Puncture | 1 | 2001 | 16 | 0.180 |
Why?
|
| Accidental Falls | 1 | 2022 | 127 | 0.180 |
Why?
|
| Anesthetics, Intravenous | 1 | 2001 | 26 | 0.180 |
Why?
|
| Mothers | 3 | 2023 | 275 | 0.180 |
Why?
|
| Propofol | 1 | 2001 | 24 | 0.180 |
Why?
|
| Point-of-Care Systems | 1 | 2023 | 131 | 0.180 |
Why?
|
| Pyridostigmine Bromide | 1 | 2021 | 5 | 0.180 |
Why?
|
| Fluid Therapy | 2 | 2019 | 49 | 0.180 |
Why?
|
| Digoxin | 1 | 2021 | 22 | 0.180 |
Why?
|
| Ureterolithiasis | 1 | 2021 | 13 | 0.180 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2022 | 159 | 0.180 |
Why?
|
| Cannula | 1 | 2020 | 26 | 0.170 |
Why?
|
| Urinary Tract Infections | 1 | 2021 | 91 | 0.170 |
Why?
|
| Pain | 2 | 2001 | 406 | 0.170 |
Why?
|
| Phenytoin | 1 | 2020 | 18 | 0.170 |
Why?
|
| Treatment Refusal | 1 | 2020 | 56 | 0.170 |
Why?
|
| Feasibility Studies | 4 | 2025 | 568 | 0.170 |
Why?
|
| Central Nervous System Infections | 1 | 2000 | 8 | 0.170 |
Why?
|
| Regional Blood Flow | 2 | 2019 | 112 | 0.170 |
Why?
|
| Misoprostol | 1 | 2020 | 9 | 0.170 |
Why?
|
| Cervical Ripening | 1 | 2020 | 11 | 0.170 |
Why?
|
| Dinoprostone | 1 | 2020 | 43 | 0.170 |
Why?
|
| Tachycardia, Sinus | 1 | 2020 | 3 | 0.170 |
Why?
|
| Oxytocics | 1 | 2020 | 14 | 0.160 |
Why?
|
| Lyme Neuroborreliosis | 2 | 2018 | 9 | 0.160 |
Why?
|
| Cervix Uteri | 1 | 2020 | 60 | 0.160 |
Why?
|
| Oxytocin | 1 | 2020 | 45 | 0.160 |
Why?
|
| Omentum | 1 | 2019 | 13 | 0.160 |
Why?
|
| Delivery, Obstetric | 1 | 2020 | 51 | 0.160 |
Why?
|
| Catheters | 1 | 2020 | 74 | 0.160 |
Why?
|
| Blood Transfusion | 2 | 2018 | 161 | 0.160 |
Why?
|
| Midwifery | 1 | 2000 | 32 | 0.160 |
Why?
|
| Noninvasive Ventilation | 1 | 2020 | 70 | 0.160 |
Why?
|
| Cross-Sectional Studies | 6 | 2023 | 2569 | 0.160 |
Why?
|
| Tachycardia | 1 | 2019 | 29 | 0.160 |
Why?
|
| Babesia microti | 2 | 2019 | 7 | 0.160 |
Why?
|
| Prednisone | 1 | 1999 | 86 | 0.160 |
Why?
|
| Visual Analog Scale | 1 | 2019 | 9 | 0.160 |
Why?
|
| Anastomotic Leak | 1 | 2019 | 36 | 0.160 |
Why?
|
| Medicare | 1 | 2004 | 610 | 0.160 |
Why?
|
| Early Medical Intervention | 1 | 2019 | 21 | 0.160 |
Why?
|
| Survival Rate | 4 | 2017 | 850 | 0.160 |
Why?
|
| Erythromycin | 1 | 2019 | 4 | 0.160 |
Why?
|
| Image Enhancement | 2 | 2000 | 192 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2010 | 755 | 0.160 |
Why?
|
| Data Interpretation, Statistical | 1 | 2020 | 194 | 0.150 |
Why?
|
| Hypokalemia | 1 | 2019 | 13 | 0.150 |
Why?
|
| Esophagectomy | 1 | 2019 | 48 | 0.150 |
Why?
|
| Middle Cerebral Artery | 2 | 2017 | 46 | 0.150 |
Why?
|
| Hemodynamics | 2 | 2017 | 248 | 0.150 |
Why?
|
| Azithromycin | 1 | 2019 | 32 | 0.150 |
Why?
|
| Snoring | 1 | 2018 | 8 | 0.150 |
Why?
|
| Blood Safety | 1 | 2018 | 7 | 0.150 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 196 | 0.150 |
Why?
|
| Esophageal Neoplasms | 1 | 2019 | 83 | 0.150 |
Why?
|
| Blood | 2 | 2015 | 30 | 0.150 |
Why?
|
| Respiratory System | 1 | 2018 | 45 | 0.150 |
Why?
|
| Panic Disorder | 1 | 2018 | 32 | 0.150 |
Why?
|
| Pulmonary Ventilation | 1 | 2018 | 38 | 0.150 |
Why?
|
| Dyspnea | 1 | 2019 | 124 | 0.150 |
Why?
|
| Glioblastoma | 1 | 2000 | 158 | 0.150 |
Why?
|
| Environmental Exposure | 2 | 2022 | 218 | 0.140 |
Why?
|
| Prenatal Care | 1 | 2000 | 170 | 0.140 |
Why?
|
| Nervous System Diseases | 1 | 1999 | 107 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1999 | 180 | 0.140 |
Why?
|
| Serologic Tests | 2 | 2017 | 37 | 0.140 |
Why?
|
| Physicians, Family | 1 | 1998 | 74 | 0.140 |
Why?
|
| Clinical Clerkship | 1 | 1998 | 91 | 0.140 |
Why?
|
| Breast Feeding | 3 | 2023 | 149 | 0.140 |
Why?
|
| Blood Flow Velocity | 3 | 2016 | 72 | 0.140 |
Why?
|
| Back Pain | 1 | 2018 | 51 | 0.140 |
Why?
|
| Sleep | 1 | 2020 | 224 | 0.140 |
Why?
|
| Brain Neoplasms | 2 | 2000 | 308 | 0.140 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2017 | 65 | 0.140 |
Why?
|
| Developmental Disabilities | 2 | 2009 | 116 | 0.140 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2017 | 24 | 0.140 |
Why?
|
| Substance-Related Disorders | 2 | 2023 | 732 | 0.130 |
Why?
|
| Acrodermatitis | 1 | 2016 | 1 | 0.130 |
Why?
|
| Patient Care Bundles | 1 | 2017 | 12 | 0.130 |
Why?
|
| Cerebral Ventricles | 1 | 1997 | 29 | 0.130 |
Why?
|
| Emergency Medical Services | 1 | 2020 | 264 | 0.130 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2017 | 34 | 0.130 |
Why?
|
| Antisickling Agents | 1 | 1996 | 5 | 0.130 |
Why?
|
| Anal Canal | 1 | 2017 | 36 | 0.130 |
Why?
|
| Hemoglobins | 2 | 2002 | 135 | 0.130 |
Why?
|
| Research | 1 | 1998 | 193 | 0.130 |
Why?
|
| Hydroxyurea | 1 | 1996 | 19 | 0.130 |
Why?
|
| Vasodilation | 1 | 2017 | 36 | 0.130 |
Why?
|
| Blood Loss, Surgical | 1 | 2017 | 65 | 0.130 |
Why?
|
| Phenylephrine | 1 | 2016 | 18 | 0.130 |
Why?
|
| Memory Disorders | 1 | 2017 | 50 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2020 | 863 | 0.130 |
Why?
|
| Arteries | 1 | 2017 | 81 | 0.130 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2009 | 23 | 0.130 |
Why?
|
| Feces | 1 | 2017 | 112 | 0.130 |
Why?
|
| Memory, Short-Term | 1 | 2017 | 60 | 0.130 |
Why?
|
| Patient Selection | 2 | 2016 | 488 | 0.130 |
Why?
|
| Congenital Hypothyroidism | 1 | 2016 | 13 | 0.130 |
Why?
|
| Thyrotropin | 1 | 2016 | 34 | 0.130 |
Why?
|
| Intubation, Intratracheal | 3 | 2025 | 204 | 0.130 |
Why?
|
| Betamethasone | 3 | 2001 | 5 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 1996 | 63 | 0.120 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2017 | 72 | 0.120 |
Why?
|
| Angina, Stable | 1 | 2016 | 11 | 0.120 |
Why?
|
| Teaching Rounds | 1 | 2016 | 11 | 0.120 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 462 | 0.120 |
Why?
|
| Logistic Models | 6 | 2021 | 1275 | 0.120 |
Why?
|
| Thrombolytic Therapy | 1 | 2017 | 190 | 0.120 |
Why?
|
| Problem-Based Learning | 1 | 2016 | 37 | 0.120 |
Why?
|
| Staphylococcus aureus | 2 | 2009 | 176 | 0.120 |
Why?
|
| Linear Models | 2 | 2015 | 409 | 0.120 |
Why?
|
| Walking | 1 | 2017 | 238 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 145 | 0.120 |
Why?
|
| Lead | 1 | 2015 | 43 | 0.110 |
Why?
|
| Prognosis | 5 | 2013 | 1750 | 0.110 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2017 | 172 | 0.110 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2017 | 126 | 0.110 |
Why?
|
| Clostridium Infections | 1 | 2015 | 49 | 0.110 |
Why?
|
| Mentors | 1 | 2015 | 119 | 0.110 |
Why?
|
| Multivariate Analysis | 5 | 2016 | 935 | 0.110 |
Why?
|
| Hypertension | 2 | 2019 | 584 | 0.110 |
Why?
|
| Microscopy | 1 | 2015 | 91 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 207 | 0.110 |
Why?
|
| Laryngeal Masks | 1 | 2014 | 26 | 0.110 |
Why?
|
| Gastroenterology | 1 | 2014 | 42 | 0.110 |
Why?
|
| Cause of Death | 1 | 1995 | 221 | 0.110 |
Why?
|
| Glucocorticoids | 3 | 2001 | 188 | 0.110 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2015 | 157 | 0.110 |
Why?
|
| Anesthesia | 1 | 2014 | 51 | 0.110 |
Why?
|
| Catheterization, Peripheral | 1 | 2014 | 53 | 0.110 |
Why?
|
| Fetal Diseases | 2 | 2007 | 21 | 0.110 |
Why?
|
| Splanchnic Circulation | 3 | 2019 | 16 | 0.110 |
Why?
|
| Nuclear Power Plants | 1 | 2013 | 1 | 0.110 |
Why?
|
| Cardiac Catheterization | 1 | 2016 | 281 | 0.110 |
Why?
|
| Electrocardiography | 3 | 2024 | 552 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 345 | 0.100 |
Why?
|
| Hospital Mortality | 1 | 2018 | 874 | 0.100 |
Why?
|
| Prenatal Diagnosis | 2 | 2007 | 39 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2017 | 266 | 0.100 |
Why?
|
| Lung | 1 | 2018 | 953 | 0.100 |
Why?
|
| Neurosurgical Procedures | 1 | 2013 | 99 | 0.100 |
Why?
|
| Drug Therapy, Combination | 3 | 2017 | 463 | 0.100 |
Why?
|
| Odds Ratio | 5 | 2018 | 768 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2017 | 495 | 0.100 |
Why?
|
| Myocardial Infarction | 2 | 2018 | 912 | 0.100 |
Why?
|
| Bed Occupancy | 1 | 2012 | 12 | 0.100 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2013 | 78 | 0.100 |
Why?
|
| Baths | 1 | 2012 | 7 | 0.100 |
Why?
|
| State Government | 1 | 2012 | 32 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 35 | 0.100 |
Why?
|
| Chlorhexidine | 1 | 2012 | 19 | 0.100 |
Why?
|
| Blood Group Incompatibility | 1 | 2012 | 10 | 0.100 |
Why?
|
| Vital Signs | 1 | 2012 | 12 | 0.100 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2012 | 30 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1254 | 0.090 |
Why?
|
| Nephrolithiasis | 1 | 2011 | 8 | 0.090 |
Why?
|
| Antibodies, Bacterial | 2 | 2013 | 181 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2012 | 43 | 0.090 |
Why?
|
| Housekeeping, Hospital | 1 | 2011 | 4 | 0.090 |
Why?
|
| Desmin | 1 | 2011 | 5 | 0.090 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2011 | 12 | 0.090 |
Why?
|
| Ankle | 1 | 2011 | 28 | 0.090 |
Why?
|
| Mucin-1 | 1 | 2011 | 14 | 0.090 |
Why?
|
| Coronary Circulation | 1 | 2011 | 52 | 0.090 |
Why?
|
| Mesothelioma | 1 | 2011 | 28 | 0.090 |
Why?
|
| Diabetic Retinopathy | 1 | 2012 | 53 | 0.090 |
Why?
|
| Epithelium | 1 | 2011 | 96 | 0.090 |
Why?
|
| Condoms | 1 | 2011 | 48 | 0.090 |
Why?
|
| Sex Education | 1 | 2011 | 25 | 0.090 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2011 | 51 | 0.090 |
Why?
|
| Peer Group | 1 | 2012 | 105 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 2 | 2023 | 84 | 0.090 |
Why?
|
| Anti-Ulcer Agents | 1 | 2010 | 9 | 0.090 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2011 | 18 | 0.090 |
Why?
|
| Vitamin D | 1 | 2012 | 140 | 0.090 |
Why?
|
| Peptic Ulcer | 1 | 2010 | 20 | 0.090 |
Why?
|
| Histamine H2 Antagonists | 1 | 2010 | 15 | 0.090 |
Why?
|
| Physicians, Primary Care | 1 | 2011 | 78 | 0.090 |
Why?
|
| Baroreflex | 2 | 2021 | 22 | 0.090 |
Why?
|
| Angina Pectoris | 1 | 2010 | 38 | 0.090 |
Why?
|
| Chlamydia Infections | 1 | 2011 | 75 | 0.090 |
Why?
|
| Birth Weight | 4 | 2015 | 85 | 0.090 |
Why?
|
| Syndrome | 1 | 2010 | 180 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2004 | 172 | 0.080 |
Why?
|
| Health Policy | 1 | 2012 | 192 | 0.080 |
Why?
|
| Proton Pump Inhibitors | 1 | 2010 | 42 | 0.080 |
Why?
|
| Cell Phone | 1 | 2010 | 44 | 0.080 |
Why?
|
| Exercise Therapy | 2 | 2021 | 104 | 0.080 |
Why?
|
| Urban Population | 1 | 2011 | 193 | 0.080 |
Why?
|
| Metabolic Syndrome | 1 | 2011 | 142 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 2 | 2025 | 517 | 0.080 |
Why?
|
| Inappropriate Prescribing | 1 | 2010 | 66 | 0.080 |
Why?
|
| Stroke Volume | 2 | 2020 | 332 | 0.080 |
Why?
|
| Bronchiolitis | 1 | 2009 | 17 | 0.080 |
Why?
|
| Lawyers | 1 | 2009 | 2 | 0.080 |
Why?
|
| Bacteriological Techniques | 1 | 2009 | 28 | 0.080 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2010 | 168 | 0.080 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2009 | 1 | 0.080 |
Why?
|
| Anemia, Aplastic | 1 | 2009 | 10 | 0.080 |
Why?
|
| Anemia | 1 | 2011 | 127 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 214 | 0.080 |
Why?
|
| Adolescent Behavior | 1 | 2011 | 193 | 0.080 |
Why?
|
| Whooping Cough | 1 | 2009 | 10 | 0.080 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2009 | 57 | 0.080 |
Why?
|
| Equipment Contamination | 1 | 2009 | 33 | 0.080 |
Why?
|
| Klebsiella Infections | 1 | 2009 | 22 | 0.080 |
Why?
|
| Gonorrhea | 1 | 2011 | 157 | 0.080 |
Why?
|
| Klebsiella pneumoniae | 1 | 2009 | 28 | 0.080 |
Why?
|
| Multiple Birth Offspring | 1 | 2009 | 1 | 0.080 |
Why?
|
| Neutropenia | 1 | 2009 | 67 | 0.080 |
Why?
|
| Patient Compliance | 2 | 2009 | 360 | 0.080 |
Why?
|
| Anaphylaxis | 3 | 1995 | 40 | 0.080 |
Why?
|
| Tocolytic Agents | 2 | 1999 | 3 | 0.080 |
Why?
|
| Magnesium Sulfate | 2 | 1999 | 9 | 0.080 |
Why?
|
| Disease Outbreaks | 1 | 2009 | 115 | 0.070 |
Why?
|
| Program Development | 1 | 2009 | 207 | 0.070 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2009 | 56 | 0.070 |
Why?
|
| Stroke | 1 | 2018 | 1191 | 0.070 |
Why?
|
| Sex Factors | 4 | 2016 | 979 | 0.070 |
Why?
|
| Pregnancy Outcome | 2 | 2000 | 193 | 0.070 |
Why?
|
| Cardiology | 1 | 2010 | 167 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2009 | 107 | 0.070 |
Why?
|
| Comorbidity | 4 | 2017 | 1118 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2013 | 621 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2016 | 801 | 0.070 |
Why?
|
| Heart Defects, Congenital | 1 | 2009 | 102 | 0.070 |
Why?
|
| Methicillin Resistance | 2 | 2009 | 23 | 0.070 |
Why?
|
| Amniotic Fluid | 2 | 1998 | 8 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2008 | 75 | 0.070 |
Why?
|
| Ultrasonography | 2 | 2023 | 483 | 0.070 |
Why?
|
| Hepatectomy | 1 | 2008 | 63 | 0.070 |
Why?
|
| Gastroschisis | 1 | 2007 | 2 | 0.070 |
Why?
|
| Continuity of Patient Care | 1 | 2009 | 174 | 0.070 |
Why?
|
| Arterial Pressure | 2 | 2017 | 27 | 0.070 |
Why?
|
| Veterans | 1 | 1995 | 764 | 0.070 |
Why?
|
| Health Behavior | 2 | 2011 | 466 | 0.070 |
Why?
|
| Coronary Artery Disease | 1 | 2010 | 310 | 0.060 |
Why?
|
| Contrast Media | 3 | 1995 | 424 | 0.060 |
Why?
|
| Body Weight | 2 | 2005 | 377 | 0.060 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 2 | 2017 | 25 | 0.060 |
Why?
|
| Professional Competence | 1 | 2007 | 93 | 0.060 |
Why?
|
| Staphylococcal Infections | 2 | 2009 | 129 | 0.060 |
Why?
|
| Healthy Volunteers | 2 | 2017 | 74 | 0.060 |
Why?
|
| India | 1 | 2006 | 158 | 0.060 |
Why?
|
| Blood Coagulation Disorders | 2 | 2003 | 23 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2008 | 178 | 0.060 |
Why?
|
| Severity of Illness Index | 5 | 2016 | 1543 | 0.060 |
Why?
|
| Serum Albumin | 1 | 2005 | 47 | 0.060 |
Why?
|
| Atrial Fibrillation | 1 | 2014 | 837 | 0.060 |
Why?
|
| Liver Transplantation | 1 | 2008 | 215 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 417 | 0.060 |
Why?
|
| Mitral Valve | 1 | 2006 | 118 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 298 | 0.060 |
Why?
|
| HL-60 Cells | 1 | 2025 | 24 | 0.060 |
Why?
|
| Counseling | 1 | 2007 | 362 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 297 | 0.060 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2006 | 165 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2005 | 137 | 0.060 |
Why?
|
| Ambulatory Care | 2 | 2012 | 311 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 670 | 0.060 |
Why?
|
| Tertiary Care Centers | 2 | 2017 | 108 | 0.060 |
Why?
|
| Reference Standards | 1 | 2004 | 73 | 0.060 |
Why?
|
| Biomarkers | 2 | 2011 | 1396 | 0.060 |
Why?
|
| Auditory Perception | 1 | 2004 | 36 | 0.060 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2004 | 1 | 0.050 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 2004 | 3 | 0.050 |
Why?
|
| Fosinopril | 1 | 2003 | 2 | 0.050 |
Why?
|
| Exercise | 2 | 2021 | 939 | 0.050 |
Why?
|
| Computers | 1 | 2024 | 49 | 0.050 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2003 | 9 | 0.050 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2003 | 33 | 0.050 |
Why?
|
| Obesity | 1 | 2011 | 1230 | 0.050 |
Why?
|
| CA-125 Antigen | 1 | 2003 | 4 | 0.050 |
Why?
|
| Apgar Score | 2 | 2020 | 11 | 0.050 |
Why?
|
| Blood Coagulation Tests | 1 | 2003 | 5 | 0.050 |
Why?
|
| Vancomycin Resistance | 1 | 2003 | 4 | 0.050 |
Why?
|
| Palliative Care | 1 | 2005 | 228 | 0.050 |
Why?
|
| Enterococcus | 1 | 2003 | 10 | 0.050 |
Why?
|
| Ceftriaxone | 1 | 2003 | 19 | 0.050 |
Why?
|
| Infusions, Intravenous | 3 | 2019 | 174 | 0.050 |
Why?
|
| Lactation | 1 | 2023 | 69 | 0.050 |
Why?
|
| Chest Pain | 1 | 2024 | 84 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2023 | 88 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2003 | 34 | 0.050 |
Why?
|
| Environmental Health | 1 | 2022 | 15 | 0.050 |
Why?
|
| Growth Hormone | 1 | 2022 | 18 | 0.050 |
Why?
|
| Mass Screening | 2 | 2006 | 690 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2003 | 143 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2003 | 185 | 0.050 |
Why?
|
| Workflow | 1 | 2023 | 69 | 0.050 |
Why?
|
| Epistaxis | 1 | 2002 | 5 | 0.050 |
Why?
|
| Observer Variation | 2 | 2000 | 213 | 0.050 |
Why?
|
| Mastectomy | 1 | 2022 | 58 | 0.050 |
Why?
|
| Urinary Catheters | 1 | 2021 | 5 | 0.050 |
Why?
|
| Documentation | 1 | 2023 | 128 | 0.050 |
Why?
|
| Tertiary Healthcare | 1 | 2021 | 15 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2003 | 192 | 0.050 |
Why?
|
| Mastectomy, Segmental | 1 | 2022 | 46 | 0.050 |
Why?
|
| Urinary Catheterization | 1 | 2021 | 20 | 0.050 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 1993 | 150 | 0.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2003 | 198 | 0.050 |
Why?
|
| Secretin | 1 | 2001 | 4 | 0.050 |
Why?
|
| Anesthesia Recovery Period | 1 | 2001 | 5 | 0.050 |
Why?
|
| Midazolam | 1 | 2001 | 12 | 0.050 |
Why?
|
| Drug Evaluation | 1 | 2001 | 19 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2021 | 69 | 0.050 |
Why?
|
| Psychomotor Agitation | 1 | 2001 | 19 | 0.040 |
Why?
|
| Gastrointestinal Agents | 1 | 2001 | 26 | 0.040 |
Why?
|
| Spinal Cord Injuries | 1 | 2001 | 50 | 0.040 |
Why?
|
| Airway Management | 1 | 2021 | 57 | 0.040 |
Why?
|
| Oximetry | 1 | 2001 | 48 | 0.040 |
Why?
|
| Laryngoscopy | 1 | 2021 | 61 | 0.040 |
Why?
|
| Hypnotics and Sedatives | 1 | 2001 | 66 | 0.040 |
Why?
|
| Hypovolemia | 1 | 2021 | 17 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2003 | 217 | 0.040 |
Why?
|
| Dizziness | 1 | 2021 | 18 | 0.040 |
Why?
|
| Hemorrhage | 2 | 2018 | 267 | 0.040 |
Why?
|
| Sympathetic Nervous System | 1 | 2021 | 35 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2021 | 53 | 0.040 |
Why?
|
| Fetal Death | 1 | 2000 | 14 | 0.040 |
Why?
|
| Safety | 1 | 2001 | 145 | 0.040 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2021 | 47 | 0.040 |
Why?
|
| Genotype | 2 | 2015 | 664 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2021 | 49 | 0.040 |
Why?
|
| Fentanyl | 1 | 2001 | 76 | 0.040 |
Why?
|
| Research Design | 1 | 2004 | 573 | 0.040 |
Why?
|
| Endometritis | 1 | 2020 | 4 | 0.040 |
Why?
|
| Postpartum Hemorrhage | 1 | 2020 | 5 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2000 | 1613 | 0.040 |
Why?
|
| Anesthesia, Epidural | 1 | 2020 | 24 | 0.040 |
Why?
|
| Cardiography, Impedance | 1 | 2020 | 4 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 451 | 0.040 |
Why?
|
| Echocardiography | 1 | 2003 | 501 | 0.040 |
Why?
|
| Pulmonary Surfactants | 1 | 2000 | 12 | 0.040 |
Why?
|
| Suburban Health | 1 | 1999 | 2 | 0.040 |
Why?
|
| Hospital Bed Capacity | 1 | 2019 | 27 | 0.040 |
Why?
|
| Rehydration Solutions | 1 | 2019 | 3 | 0.040 |
Why?
|
| Head Protective Devices | 1 | 1999 | 19 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2000 | 972 | 0.040 |
Why?
|
| Platelet Count | 3 | 2004 | 26 | 0.040 |
Why?
|
| Bicycling | 1 | 1999 | 21 | 0.040 |
Why?
|
| Mammography | 1 | 2022 | 280 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2019 | 78 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 66 | 0.040 |
Why?
|
| Amoxicillin | 1 | 2019 | 8 | 0.040 |
Why?
|
| Mineralocorticoids | 1 | 2019 | 2 | 0.040 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2019 | 2 | 0.040 |
Why?
|
| Ampicillin | 1 | 2019 | 12 | 0.040 |
Why?
|
| Craniocerebral Trauma | 1 | 1999 | 55 | 0.040 |
Why?
|
| Propensity Score | 1 | 2019 | 156 | 0.040 |
Why?
|
| Cesarean Section | 1 | 2020 | 99 | 0.040 |
Why?
|
| Recovery of Function | 2 | 2016 | 287 | 0.040 |
Why?
|
| North America | 2 | 2009 | 111 | 0.040 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1998 | 7 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2000 | 2167 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2019 | 171 | 0.040 |
Why?
|
| Motor Activity | 1 | 2001 | 346 | 0.040 |
Why?
|
| Athletic Injuries | 1 | 1999 | 83 | 0.040 |
Why?
|
| Arousal | 1 | 2018 | 42 | 0.040 |
Why?
|
| Supine Position | 1 | 2018 | 32 | 0.040 |
Why?
|
| Biopsy | 1 | 2000 | 444 | 0.040 |
Why?
|
| Practice Management, Medical | 1 | 1998 | 21 | 0.040 |
Why?
|
| Acute Lung Injury | 1 | 2018 | 45 | 0.040 |
Why?
|
| Respiration | 1 | 2018 | 89 | 0.040 |
Why?
|
| Job Satisfaction | 1 | 1998 | 137 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2019 | 193 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2000 | 777 | 0.030 |
Why?
|
| Fetal Blood | 1 | 1997 | 73 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2017 | 28 | 0.030 |
Why?
|
| Hirudins | 1 | 2017 | 12 | 0.030 |
Why?
|
| Plethysmography, Impedance | 1 | 2017 | 3 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2017 | 38 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 734 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 66 | 0.030 |
Why?
|
| Slovenia | 1 | 2016 | 3 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 860 | 0.030 |
Why?
|
| Fetal Hemoglobin | 1 | 1996 | 13 | 0.030 |
Why?
|
| Creatinine | 1 | 2017 | 136 | 0.030 |
Why?
|
| Bacterial Toxins | 1 | 2017 | 61 | 0.030 |
Why?
|
| Population Surveillance | 2 | 2008 | 206 | 0.030 |
Why?
|
| Uterus | 1 | 1996 | 42 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2017 | 123 | 0.030 |
Why?
|
| Heparin | 1 | 2017 | 116 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2017 | 265 | 0.030 |
Why?
|
| Xenon | 1 | 2015 | 8 | 0.030 |
Why?
|
| Michigan | 1 | 1995 | 43 | 0.030 |
Why?
|
| Brain Diseases | 1 | 1996 | 76 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2017 | 410 | 0.030 |
Why?
|
| Warfare | 1 | 1995 | 41 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 701 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2011 | 498 | 0.030 |
Why?
|
| Laryngismus | 1 | 2014 | 3 | 0.030 |
Why?
|
| Methyl Ethers | 1 | 2014 | 7 | 0.030 |
Why?
|
| Constriction | 1 | 2014 | 9 | 0.030 |
Why?
|
| Vietnam | 1 | 1995 | 173 | 0.030 |
Why?
|
| Age Distribution | 1 | 1995 | 259 | 0.030 |
Why?
|
| Anesthetics, Inhalation | 1 | 2014 | 18 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2015 | 121 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2015 | 136 | 0.030 |
Why?
|
| Organizational Innovation | 1 | 2015 | 82 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2016 | 176 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2008 | 502 | 0.030 |
Why?
|
| Operative Time | 1 | 2014 | 92 | 0.030 |
Why?
|
| Mortality | 1 | 1995 | 160 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2013 | 115 | 0.030 |
Why?
|
| Microsurgery | 1 | 2013 | 51 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 1995 | 203 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2005 | 581 | 0.030 |
Why?
|
| Radiography | 1 | 1995 | 548 | 0.030 |
Why?
|
| Radiosurgery | 1 | 2013 | 62 | 0.030 |
Why?
|
| Algorithms | 1 | 2018 | 1002 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 105 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 2013 | 199 | 0.020 |
Why?
|
| Health Status | 1 | 2015 | 435 | 0.020 |
Why?
|
| Respiratory Rate | 1 | 2012 | 15 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 608 | 0.020 |
Why?
|
| Mental Health | 1 | 2015 | 371 | 0.020 |
Why?
|
| Curriculum | 1 | 2016 | 591 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 459 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2012 | 142 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2011 | 88 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2017 | 766 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2012 | 246 | 0.020 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2010 | 3 | 0.020 |
Why?
|
| Defensive Medicine | 1 | 2010 | 3 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2004 | 753 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2016 | 725 | 0.020 |
Why?
|
| Inpatients | 1 | 2013 | 303 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 2010 | 57 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 214 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2003 | 738 | 0.020 |
Why?
|
| Embolization, Therapeutic | 1 | 2013 | 316 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2011 | 457 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 337 | 0.020 |
Why?
|
| Humidity | 1 | 2009 | 12 | 0.020 |
Why?
|
| Data Collection | 1 | 2011 | 384 | 0.020 |
Why?
|
| Schools | 1 | 2011 | 166 | 0.020 |
Why?
|
| Nose | 1 | 2009 | 31 | 0.020 |
Why?
|
| Malpractice | 1 | 2009 | 18 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2010 | 286 | 0.020 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2009 | 11 | 0.020 |
Why?
|
| Tetanus | 1 | 2009 | 5 | 0.020 |
Why?
|
| DNA Fingerprinting | 1 | 2009 | 8 | 0.020 |
Why?
|
| Drug Resistance, Microbial | 1 | 2009 | 46 | 0.020 |
Why?
|
| Bordetella pertussis | 1 | 2009 | 9 | 0.020 |
Why?
|
| Diphtheria | 1 | 2009 | 5 | 0.020 |
Why?
|
| Bacterial Typing Techniques | 1 | 2009 | 12 | 0.020 |
Why?
|
| Perception | 1 | 2010 | 174 | 0.020 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2009 | 73 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2009 | 130 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2010 | 209 | 0.020 |
Why?
|
| Education, Special | 1 | 2009 | 11 | 0.020 |
Why?
|
| Occupational Therapy | 1 | 2009 | 12 | 0.020 |
Why?
|
| Speech Therapy | 1 | 2009 | 16 | 0.020 |
Why?
|
| Virulence | 1 | 2009 | 193 | 0.020 |
Why?
|
| Injections, Intravenous | 2 | 2003 | 156 | 0.020 |
Why?
|
| Maternal Age | 1 | 2009 | 33 | 0.020 |
Why?
|
| Students | 1 | 2011 | 217 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2009 | 52 | 0.020 |
Why?
|
| Physical Therapy Modalities | 1 | 2009 | 48 | 0.020 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2009 | 65 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2010 | 193 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 263 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2012 | 866 | 0.020 |
Why?
|
| Appointments and Schedules | 1 | 2009 | 60 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2008 | 99 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 253 | 0.020 |
Why?
|
| Professional-Patient Relations | 1 | 2009 | 128 | 0.020 |
Why?
|
| Living Donors | 1 | 2008 | 77 | 0.020 |
Why?
|
| Fetal Weight | 1 | 2007 | 1 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 242 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2009 | 209 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 537 | 0.020 |
Why?
|
| Systole | 1 | 2006 | 109 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 1993 | 834 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2006 | 134 | 0.020 |
Why?
|
| Heart Atria | 1 | 2006 | 138 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2005 | 94 | 0.020 |
Why?
|
| Skilled Nursing Facilities | 1 | 2005 | 83 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2009 | 479 | 0.010 |
Why?
|
| Health Surveys | 1 | 2006 | 313 | 0.010 |
Why?
|
| Remission Induction | 1 | 2004 | 148 | 0.010 |
Why?
|
| Myometrium | 1 | 2003 | 15 | 0.010 |
Why?
|
| Placebos | 1 | 2003 | 72 | 0.010 |
Why?
|
| Anti-Retroviral Agents | 1 | 2003 | 76 | 0.010 |
Why?
|
| Gram-Negative Bacteria | 1 | 2003 | 57 | 0.010 |
Why?
|
| ROC Curve | 1 | 2003 | 281 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2003 | 278 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2003 | 224 | 0.010 |
Why?
|
| Partial Thromboplastin Time | 1 | 2002 | 9 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2003 | 369 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2003 | 177 | 0.010 |
Why?
|
| X-Rays | 1 | 2001 | 46 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2003 | 207 | 0.010 |
Why?
|
| Organ Size | 1 | 2001 | 172 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2001 | 185 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2001 | 161 | 0.010 |
Why?
|
| Extraembryonic Membranes | 1 | 2000 | 5 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2001 | 204 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2000 | 71 | 0.010 |
Why?
|
| Placenta | 1 | 2000 | 61 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2003 | 297 | 0.010 |
Why?
|
| Recurrence | 1 | 2002 | 643 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2001 | 230 | 0.010 |
Why?
|
| Cognition | 1 | 2003 | 484 | 0.010 |
Why?
|
| Infant Mortality | 1 | 1999 | 20 | 0.010 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1999 | 36 | 0.010 |
Why?
|
| Rats | 1 | 2001 | 1977 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 1997 | 15 | 0.010 |
Why?
|
| Erythropoietin | 1 | 1997 | 39 | 0.010 |
Why?
|
| Animals | 2 | 2008 | 20634 | 0.010 |
Why?
|
| Erythropoiesis | 1 | 1997 | 36 | 0.010 |
Why?
|
| Amniocentesis | 1 | 1996 | 5 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1996 | 33 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2001 | 738 | 0.010 |
Why?
|
| Adrenoleukodystrophy | 1 | 1996 | 8 | 0.010 |
Why?
|
| Radiographic Image Enhancement | 1 | 1996 | 98 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 1996 | 321 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1996 | 149 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2001 | 2180 | 0.010 |
Why?
|
| Multiple Sclerosis | 1 | 1996 | 218 | 0.010 |
Why?
|
| Bronchial Spasm | 1 | 1991 | 8 | 0.010 |
Why?
|
| Urography | 1 | 1991 | 13 | 0.010 |
Why?
|